Xinhua News Agency, Chongqing, January 25 (Reporter Ke Gaoyang) Cardiovascular diseases such as atherosclerosis are a major killer of human health.
Researchers in my country have recently made new progress in the field of targeted therapy of atherosclerosis. The relevant research results have been published as the cover article of the international journal Therapeutic Diagnosis in the field of biomedicine.
The "China Cardiovascular Health and Disease Report 2019" issued by the National Center for Cardiovascular Diseases shows that the number of cardiovascular diseases in my country currently exceeds 330 million, and the prevalence and mortality rates are on the rise.
Among them, atherosclerosis is a typical chronic inflammatory vascular disease, which is the main pathological basis of cardiovascular disease.
"At present, the use of nano-drug delivery systems to treat atherosclerosis has become a research hotspot, but traditional nano-drug delivery systems have problems such as short cycle life, lack of specific targeting, and poor controllability of drug release." Corresponding author of the paper, Said Liao Xiaoling, a professor at Chongqing University of Science and Technology.
Based on this, Xiaoling Liao’s research team cooperated with the research group of Professor Wang Guixue of Chongqing University to use a bionic design strategy to coat macrophage membranes on nano-drugs to construct drugs with sustained drug release, long-term blood circulation and active targeting of atherosclerosis Deliver functional bionic nano-drugs MM/RAPNPs.
The results of in vivo animal experiments show that the bionic nano-drug can safely and effectively inhibit the development and deterioration of atherosclerosis.
Reviewers believe that this research provides a new design idea for the targeted therapy of atherosclerosis, which has important scientific research significance and potential clinical application value.